Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Oncogenic mechanism of Sox2 in Rb-deficient tumors

Award Number: R01CA233661
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/23/2019
PERIOD OF PERFORMANCE END DATE: 06/30/2025

Group Awards By:

View Award Description

Oncogenic mechanism of Sox2 in Rb-deficient tumors - PROJECT SUMMARY The retinoblastoma tumor suppressor (Rb) is a central gene that has been implicated in the formation of multiple solid tumors. It does so by both the regulation of cellular proliferation and driving cellular differentiation to establish cellular identity. Lack of Rb then leads to cancer, yet the mechanisms which underlie the pro- oncogenic consequences of Rb-loss are still not fully understood. A novel role for Rb in the repression of essential pluripotency genes has been identified and this repression of pluripotency serves to restrict cellular plasticity and tumor formation. One of the Rb-regulated pluripotency genes identified was Sox2 which can indeed be oncogenic in some cellular contexts. However, the mechanisms of Sox2 oncogenic activity in tumors formed by Rb-loss are currently unclear. This proposal is based upon the hypothesis that upregulation of Sox2 after Rb-loss is a crucial oncogenic driver in the Rb-loss initiated tumors, and is due in part to the ability of Sox2 to enhance cellular plasticity and upregulate progenitor-state pathways. To investigate this hypothesis, this project will aim to establish the role of Sox2 in cancer initiation upon loss of Rb. This will be achieved by the utilization of genetically engineered mouse models which will test if Sox2 is required for the initiation and growth of multiple Rb-loss initiated tumors. The role for Sox2 in the maintenance and propagation of these tumors will be studied by standard growth and transplantation assays using established mouse and human cell lines. Finally, this project will aim to elucidate the oncogenic mechanisms of Sox2 in cancer. Genomic-scale investigations into the gene network regulated by Sox2 will be examined by ChIP-seq of Sox2 in tumor cell lines in conjunction with RNA-seq, ChIP-seq of modified histones, and ATAC-seq to identify the means of regulation of the greater Sox2 network. Downstream targets will be validated by their overexpression or knockdown in tumor cell lines or GEMMs. This investigation will identify the extent that Rb-loss initiated tumors are dependent upon Sox2 and the mechanisms by which Sox2 participates in tumor development by the elucidation of the broader Sox2 network in cancer. This will serve to build a cohesive gene expression network to describe the oncogenic effects that follow Rb-loss and describe how these tumors are formed. Understanding this downstream Sox2 network may provide novel targets for the treatment of these tumors and will provide a groundwork for future investigations into the development of cancer therapeutics.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2023	SANFORD RESEARCH	801 BROADWAY N	FARGO	ND	58102	CASS	USA	Cancer Cause and Prevention Research	000	5	11/24/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $369,889 )
2023	2023	SANFORD RESEARCH	2301 E 60TH ST N	SIOUX FALLS	SD	57104	MINNEHAHA	USA	Cancer Cause and Prevention Research	000	5	6/28/2023	NON-COMPETING CONTINUATION	$369,889
														Subtotal = $369,889

Issue Date FY: 2022 ( Subtotal = $377,438 )
2022	2022	SANFORD RESEARCH	2301 E 60TH ST N	SIOUX FALLS	SD	57104	MINNEHAHA	USA	Cancer Cause and Prevention Research	000	4	7/11/2022	NON-COMPETING CONTINUATION	$377,438
														Subtotal = $377,438

Issue Date FY: 2021 ( Subtotal = $377,438 )
2021	2021	SANFORD RESEARCH	2301 E 60TH ST N	SIOUX FALLS	SD	57104	MINNEHAHA	USA	Cancer Cause and Prevention Research	000	3	6/28/2021	NON-COMPETING CONTINUATION	$377,438
														Subtotal = $377,438

Issue Date FY: 2020 ( Subtotal = $377,438 )
2020	2020	SANFORD RESEARCH	2301 E 60TH ST N	SIOUX FALLS	SD	57104	MINNEHAHA	USA	Cancer Cause and Prevention Research	000	2	6/16/2020	NON-COMPETING CONTINUATION	$377,438
														Subtotal = $377,438

Issue Date FY: 2019 ( Subtotal = $377,438 )
2019	2019	SANFORD RESEARCH	2301 E 60TH ST N	SIOUX FALLS	SD	57104	MINNEHAHA	USA	Cancer Cause and Prevention Research	000	1	7/23/2019	NEW	$377,438
														Subtotal = $377,438

Grand Total All Awards = $1,879,641

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Oncogenic mechanism of Sox2 in Rb-deficient tumors

Award Number: R01CA233661

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/23/2019

PERIOD OF PERFORMANCE END DATE: 06/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer